The High Mobility Group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 531-542

  Mussnich, Paula ^a,b   D'Angelo, Daniela ^a   Leone, Vincenza ^a   Croce, Carlo Maria ^c   Fusco, Alfredo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b MINISTRY OF EDUCATION OF BRAZIL   (Brazil)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

HMGA; MicroRNA; Thyroid cells

Indexed keywords

CYCLIN D1; CYCLIN D2; HIGH MOBILITY GROUP A PROTEIN; MICRORNA; MICRORNA 10B; MICRORNA 125B; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 34A; MICRORNA 603; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

ANAPLASTIC THYROID CANCER; ARTICLE; BINDING SITE; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; THYROID CELL; WESTERN BLOTTING; WOUND HEALING;

EID: 84878160138     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.01.002     Document Type: Article

References (57)

1. Abdulkadir S.A., Krishna S., Thanos D., Maniatis T., Strominger J.L., Ono S.J. Functional roles of the transcription factor Oct-2A and the high mobility group protein I/Y in HLA-DRA gene expression. J. Exp. Med. 1995, 182:487-500.
2. Alimonti A., Carracedo A., Clohessy J.G., Trotman L.C., Nardella C., Egia A., Salmena L., Sampieri K., Haveman W.J., Brogi E., Richardson A.L., Zhang J., Pandolfi P.P. Subtle variations in Pten dose determine cancer susceptibility. Nat. Genet. 2010, 42:454-458.
3. Arlotta P., Tai A.K., Manfioletti G., Clifford C., Jay G., Ono S.J. Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. J. Biol. Chem. 2000, 275:14394-14400.
4. Baldassarre G., Fedele M., Battista S., Vecchione A., Klein-Szanto A., Santoro M., Waldmann T.A., Azimi N., Croce C.M., Fusco A. Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. Proc. Natl. Acad. Sci. USA 2001, 98:7970-7975.
5. Baldassarre G., Battista S., Belletti B., Thakur S., Pentimalli F., Trapasso F., Fedele M., Pierantoni G., Croce C.M., Fusco A. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol. Cell. Biol. 2003, 23(7):2225-2238.
6. Baron R.M., Lopez-Guzman S., Riascos D.F., Macias A.A., Layne M.D., Cheng G., Harris C., Chung S.W., Reeves R., von Andrian U.H., Perrella M.A. Distamycin A inhibits HMGA1-binding to the P-selectin promoter and attenuates lung and liver inflammation during murine endotoxemia. PLoS One 2010, 14;5(5):e10656.
7. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
8. Berger A.H., Knudson A.G., Pandolfi P.P. A continuum model for tumor suppression. Nature 2011, 476:163-169.
9. Berlingieri M.T., Manfioletti G., Santoro M., Bandiera A., Visconti R., Giancotti V., Fusco A. Inhibition of hmgi-c protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol. Cell. Biol. 1995, 15:1545-1553.
10. Berlingieri M.T., Pierantoni G.M., Giancotti V., Santoro M., Fusco A. Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 2002, 21:2971-2980.
11. Bruni P., Boccia A., Baldassarre G., Trapasso F., Santoro M., Chiappetta G., Fusco A., Viglietto G. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 2000, 19(28):3146-3155.
12. D'Angelo D., Palmieri D., Mussnich P., Roche M., Wierinckx A., Raverot G., Fedele M., Croce C.M., Trouillas J., Fusco A. Altered MicroRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J. Clin. Endocrinol. Metab. 2012, 97:E1128-E1138.
13. Fabbri M., Croce C.M., Calin G.A. MicroRNAs. Cancer J. 2008, 14:1-6.
14. Fedele M., Battista S., Kenyon L., Baldassarre G., Fidanza V., Klein-Szanto A.J., Parlow A.F., Visone R., Pierantoni G.M., Outwater E., Santoro M., Croce C.M., Fusco A. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002, 21:3190-3198.
15. Fedele M., Pentimalli F., Baldassarre G., Battista S., Klein-Szanto A.J.P., Kenyon L., Visone R., De Martino I., Ciarmiello A., Arra C., Viglietto G., Croce C.M., Fusco A. Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 2005, 24:3427-3435.
16. Fedele M., Fidanza V., Battista S., Pentimalli F., Klein-Szanto A.J., Visone R., De Martino I., Curcio A., Morisco C., Del Vecchio L., Baldassarre G., Arra C., Viglietto G., Indolfi C., Croce C.M., Fusco A. Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res. 2006, 66(5):2536-2543.
17. Fedele M., Visone R., De Martino I., Troncone G., Palmieri D., Battista S., Ciarmiello A., Pallante P., Arra C., Melillo R.M., Helin K., Croce C.M., Fusco A. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006, 9:459-471.
18. Fedele M., Fusco A. HMGA and Cancer. Biochim. Biophys. Acta 2010, 1799:48-54.
19. Fedele M., Visone R., De Martino I., Palmieri D., Valentino T., Esposito F., Klein-Szanto A., Arra C., Ciarmiello A., Croce C.M., Fusco A. Expression of a truncated Hmga1b gene induces gigantism, lipomatosis and B-cell lymphomas in mice. Eur. J. Cancer 2011, 47:470-478.
20. Frasca F., Rustighi A., Malaguarnera R., Altamura S., Vigneri P., Del Sal G., Giancotti V., Pezzino V., Vigneri R., Manfioletti G. HMGA1 inhibits the function of p53 family members in thyroid cancer cells. Cancer Res. 2006, 66:2980-2989.
21. Fusco A., Berlingieri M.T., Di Fiore P.P., Portella G., Grieco M., Vecchio G. One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol. Cell. Biol. 1987, 7(9):3365-3370.
22. Fusco A., Fedele M. Roles of HMGA proteins in cancer. Nat. Rev. Can. 2007, 7:899-910.
23. Garofalo M., Quintavalle C., Romano G., Croce C.M., Condorelli G. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr. Mol. Med. 2012, 12:27-33.
24. Giancotti V., Pani B., D'Andrea P., Berlingieri M.T., Di Fiore P.P., Fusco A., Vecchio G., Philp R., Crane-Robinson C., Nicolas R.H. Elevated levels of a specific class of nuclear phosphoproteins in cells transformed with v-ras and v-mos oncogenes and by cotransfection with c-myc and polyoma middle T genes. EMBO J. 1987, 6(7):1981-1987.
25. Hollander M.C., Blumenthal G.M., Dennis P.A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Can. 2011, 11:289-301.
26. Jo D.H., Kim J.H., Park W.Y., Kim K.W., Yu Y.S., Kim J.H. Differential profiles of microRNAs in retinoblastoma cell lines of different proliferation and adherence patterns. J. Pediatr. Hematol. Oncol. 2011, 33:529-533.
27. Kim K., Lee H.C., Park J.L., Kim M., Kim S.Y., Noh S.M., Song K.S., Kim J.C., Kim Y.S. Epigenetic regulation of microRNA-10b and targeting of oncogenic MAPRE1 in gastric cancer. Epigenetics 2011, 6:740-751.
28. Lehming N., Thanos D., Brickman J.M., Ma J., Maniatis T., Ptashne M. An HMG-like protein that can switch a transcriptional activator to a repressor. Nature 1994, 371:175-179.
29. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
30. Li Z., Wang C., Prendergast G.C., Pestell R.G. Cyclin D1 functions in cell migration. Cell Cycle 2006, 5:2440-2442.
31. Liau S.S., Jazag A., Ito K., Whang E.E. Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells. Br. J. Cancer 2007, 96:993-1000.
32. Liaw D., Marsh D.J., Li J., Dahia P.L., Wang S.I., Zheng Z., Bose S., Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 1997, 16:64-67.
33. Liu C.G., Calin G.A., Meloon B., Gamliel N., Sevignani C., Ferracin M., Dumitru C.D., Shimizu M., Zupo S., Dono M., Alder H., Bullrich F., Negrini M., Croce C.M. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc. Natl. Acad. Sci. USA 2004, 101:9740-9744.
34. Liu Z., Zhu J., Cao H., Ren H., Fang X. miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer. Int. J. Oncol. 2012, 40:1553-1560.
35. -ΔΔCT method. Methods 2001, 25:402-408.
36. Mansueto G., Forzati F., Ferraro A., Pallante P., Bianco M., Esposito F., Iaccarino A., Troncone G., Fusco A. Identification of a new pathway for tumor progression: MicroRNA-181b Up-regulation and CBX7 down-regulation by HMGA1 protein. Genes Cancer 2010, 1(3):210-224.
37. Miska E.A. How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. Dev. 2005, 15:563-568.
38. Palmieri D., D'Angelo D., Valentino T., De Martino I., Ferraro A., Wierinckx A., Fedele M., Trouillas J., Fusco A. Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene 2012, 31:3857-3865.
39. Pierantoni G.M., Fedele M., Pentimalli F., Benvenuto G., Pero R., Viglietto G., Santoro M., Chiariotti L., Fusco A. High mobility group I (Y) proteins bind HIPK2, a serine- threonine kinase protein which inhibits cell growth. Oncogene 2001, 20:6132-6141.
40. Pierantoni G.M., Rinaldo C., Esposito F., Mottolese M., Soddu S., Fusco A. High mobility group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell. Death Differ. 2006, 13:1554-1563.
41. Reeves R., Nissen M.S. The AT DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J. Biol. Chem. 1990, 265:8573-8582.
42. Resar L.M. The high mobility group A1 gene: transforming inflammatory signals into cancer?. Cancer Res. 2010, 70:436-439.
43. Scala S., Portella G., Fedele M., Chiappetta G., Fusco A. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc. Natl. Acad. Sci. USA 2000, 97:4256-4261.
44. Sicinski P., Donaher J.L., Geng Y., Parker S.B., Gardner H., Park M.Y., Robker R.L., Richards J.S., McGinnis L.K., Biggers J.D., Eppig J.J., Bronson R.T., Elledge S.J., Weinberg R.A. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 1996, 384:470-474.
45. Soule H.D., Vazquez J., Long A., Albert S., Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. JNCI 1973, 51:1409-1416.
46. Tan E.J., Thuault S., Caja L., Carletti T., Heldin C.H., Moustakas A. Regulation of transcription factor twist expression by the DNA architectural protein high mobility group A2 during epithelial-to-mesenchymal transition. J. Biol. Chem. 2012, 287(10):7134-7145.
47. Tessari M.A., Gostissa M., Altamura S., Sgarra R., Rustighi A., Salvagno C., Caretti G., Imbriano C., Mantovani R., Del Sal G., Giancotti V., Manfioletti G. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol. Cell. Biol. 2003, 23:9104-9116.
48. Thanos D., Du W., Maniatis T. The high mobility group protein HMG I(Y) is an essential structural component of a virus-inducible enhancer complex. Cold Spring Harb. Symp. Quant. Biol. 1993, 58:73-81.
49. Thanos D., Maniatis T. The high mobility group protein HMG I(Y) is required for NF-κB-dependent virus induction of the human IFN-β gene. Cell 1992, 27:777-789.
50. Trotman L.C., Niki M., Dotan Z.A., Koutcher J.A., Di Cristofano A., Xiao A., Xiao A., Khoo A.S., Roy-Burman P., Greenberg N.M., Van Dyke T., Cordon-Cardo C., Pandolfi P.P. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003, 1:E59.
51. Vallone D., Battista S., Pierantoni G.M., Fedele M., Casalino L., Santoro M., Viglietto G., Fusco A., Verde P. Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO J. 1997, 16:5310-5321.
52. Vandenboom Ii T.G., Li Y., Philip P.A., Sarkar F.H. MicroRNA and cancer: tiny molecules with major implications. Curr. Genomics 2008, 9:97-109.
53. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., Croce C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 2006, 103:2257-2261.
54. Wood L.J., Maher J.F., Bunton T.E., Resar L.M. The oncogenic properties of the HMG-I gene family. Cancer Res. 2000, 60:4256-4261.
55. Wu J., Liu Z., Shao C., Gong Y., Hernando E., Lee P., Narita M., Muller W., Liu J., Wei J.J. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res. 2011, 71(2):349-359.
56. Xu Y., Sumter T.F., Bhattacharya R., Tesfaye A., Fuchs E.J., Wood L.J., Huso D.L., Resar L.M. The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res. 2004, 64:3371-3375.
57. Zamore P.D., Haley B. Ribo-genome: the big world of small RNAs. Science 2005, 309:1519-1524.